Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
Abstract Cancers harboring mutations in the Kirsten rat sarcoma homolog (KRAS) gene have been associated with poor prognosis and lack of targeted therapies. KRAS mutations occur in approximately one in four patients diagnosed with non-small cell lung cancer (NSCLC) with KRAS G12C mutations harbored...
Guardado en:
Autores principales: | Gabriela Palma, Faisal Khurshid, Kevin Lu, Brian Woodward, Hatim Husain |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4bf6f3db8dc04db6a4984258c49d0174 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
por: Shaima’a Hamarsheh, et al.
Publicado: (2020) -
p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
por: Alejandro Ruiz-Patiño, et al.
Publicado: (2022) -
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
por: Tatu Pantsar
Publicado: (2020) -
Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
por: Soonsil Hyun, et al.
Publicado: (2021) -
Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
por: Yoshihito Kano, et al.
Publicado: (2019)